204 related articles for article (PubMed ID: 22564724)
1. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
[TBL] [Abstract][Full Text] [Related]
2. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
3. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
4. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
Sato S; Drake AW; Tsuji I; Fan J
PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
Chang C; Takayanagi A; Yoshida T; Shimizu N
Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
7. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
[TBL] [Abstract][Full Text] [Related]
8. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
9. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
10. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
Grabowska MM; Sandhu B; Day ML
Cell Signal; 2012 Feb; 24(2):532-538. PubMed ID: 22024284
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy.
Dowlati A; Nethery D; Kern JA
Mol Cancer Ther; 2004 Apr; 3(4):459-63. PubMed ID: 15078989
[TBL] [Abstract][Full Text] [Related]
12. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
Hur BU; Yoon JB; Liu LK; Cha SH
Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
[TBL] [Abstract][Full Text] [Related]
13. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
14. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
Zhou Y; Drummond DC; Zou H; Hayes ME; Adams GP; Kirpotin DB; Marks JD
J Mol Biol; 2007 Aug; 371(4):934-47. PubMed ID: 17602702
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Gialeli Ch; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
Invest New Drugs; 2013 Jun; 31(3):516-24. PubMed ID: 22956286
[TBL] [Abstract][Full Text] [Related]
16. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Myers MV; Manning HC; Coffey RJ; Liebler DC
Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
[TBL] [Abstract][Full Text] [Related]
17. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
19. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
20. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
